SCYNEXIS (SCYX) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 was $0.7M, down from $131.5M in Q2 2023, reflecting the absence of a large one-time license payment from GSK in the prior year.

• Net loss for Q2 2024 was $14.5M, compared to net income of $122.3M in Q2 2023, due to the prior year’s GSK license revenue.

• Ongoing product recall and clinical hold on ibrexafungerp following manufacturing cross-contamination concerns; no new product revenue recognized in 2024.

• SCY-247, a next-generation antifungal, remains in preclinical development with a Phase 1 study planned for Q4 2024.

• Cash, cash equivalents, and investments totaled $83.7M as of June 30, 2024, with projections of a cash runway of at least 12 months to over two years.

Financial highlights

• Q2 2024 total revenue: $0.7M (all license revenue); Q2 2023: $131.5M (mainly GSK license payment).

• Net loss Q2 2024: $14.5M; net income Q2 2023: $122.3M.

• Operating expenses Q2 2024: $10.0M, down 33% year-over-year, mainly due to lower SG&A and R&D.

• Cash used in operations for H1 2024: $14.9M; net cash provided by operations H1 2023: $55.5M.

• No product revenue recognized in 2024 due to product recall.

Outlook and guidance

• Capital resources expected to fund operations for at least 12 months from June 30, 2024, with some projections extending beyond two years.

• Anticipates initiating Phase 1 study for SCY-247 in Q4 2024.

• Expects to collect a $10M milestone from GSK in Q3 2024 for completed clinical study reports.

• Plans to restart Phase 3 MARIO study in invasive candidiasis.

• Ongoing efforts to resolve clinical hold and resume ibrexafungerp studies; new manufacturing agreements in place.